Literature DB >> 6173507

Alphafetoprotein in congenital biliary atresia and neonatal hepatitis.

J Uchino, Y Hata, F Sasaki, Y Une, T Itoh, Y Kasai.   

Abstract

Alphafetoprotein (AFP) production was investigated clinically and histologically in cases of congenital biliary atresia and neonatal hepatitis. While serum AFP levels were all higher than 16,000 ng/ml in seven patients with neonatal hepatitis, they were less than 10,000 ng/ml in 50 per cent of 12 patients with biliary atresia. Therefore, serum AFP levels below 10,000 ng/ml were suggestive of a diagnosis of biliary atresia. A number of AFP granules were identified in the liver cells and multinucleated giant cells in patients with neonatal hepatitis and biliary atresia, using an immunoperoxidase method. The serum AFP levels paralleled the number of cells with AFP granules. However, no characteristic differences in distribution of these granules occurred in the hepatic cells and giant cells. The AFP producing mechanism was qualitatively the same in neonatal hepatitis and biliary atresia. These phenomena suggest that congenital biliary atresia and neonatal hepatitis may have the same pathogenesis.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6173507     DOI: 10.1007/BF02469029

Source DB:  PubMed          Journal:  Jpn J Surg        ISSN: 0047-1909


  16 in total

1.  MORPHOLOGIC STUDIES IN NEONATAL CHOLESTASIS WITH EMPHASIS ON GIANT CELLS.

Authors:  F SCHAFFNER; H POPPER
Journal:  Ann N Y Acad Sci       Date:  1963-12-30       Impact factor: 5.691

2.  Neonatal jaundice with giant cell transformation of the hepatic parenchyma.

Authors:  H F SMETANA; F B JOHNSON
Journal:  Am J Pathol       Date:  1955 Jul-Aug       Impact factor: 4.307

3.  Differentiation between neonatal hepatitis and biliary atresia by measuring serum-alpha-fetoprotein.

Authors:  P M Zeltzer; R C Neerhout; E W Fonkalsrud; E R Stiehm
Journal:  Lancet       Date:  1974-03-09       Impact factor: 79.321

4.  alpha-Fetoprotein in ill infants.

Authors:  K Y Kang; K Higashino; Y Takahashi; M Hashinotsume; Y Yamamura
Journal:  N Engl J Med       Date:  1972-07-06       Impact factor: 91.245

5.  Occurrence of fetoprotein in patients with neoplasms and non-neoplastic diseases.

Authors:  J Masopust; K Kithier; J Rádl; J Koutecký; L Kotál
Journal:  Int J Cancer       Date:  1968-05-15       Impact factor: 7.396

6.  In vitro response of foetal lymphocytes to PHA, and a factor plasma which suppresses the PHA response of adult lymphocytes.

Authors:  J Ayoub; S Kasakura
Journal:  Clin Exp Immunol       Date:  1971-03       Impact factor: 4.330

7.  Serum alpha-fetoprotein levels in extrahepatic biliary atresia, idiopathic neonatal hepatitis and alpha-1-antitrypsin deficiency (PiZ).

Authors:  D I Johnston; A P Mowat; H Orr; J Kohn
Journal:  Acta Paediatr Scand       Date:  1976-09

8.  The dynamics of alpha-fetoprotein and albumin synthesis in human and rat liver during normal ontogeny.

Authors:  N C Nayak; I Mital
Journal:  Am J Pathol       Date:  1977-02       Impact factor: 4.307

9.  Diagnostic significance of alpha-fetoproteins in neonatal hyperbilirubinaemias and primary cancer of the liver in adults.

Authors:  J Milosavljevic; M Stajic; N Vilhar
Journal:  Acta Hepatogastroenterol (Stuttg)       Date:  1977-02

10.  Demonstration of the inhibitory effect of human alpha-fetoprotein on in vitro transformation of human lymphocytes.

Authors:  S Yachnin
Journal:  Proc Natl Acad Sci U S A       Date:  1976-08       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.